Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a pharma player with a focus on the rare disease segment. Its treatment for Netherton syndrome has been gaining interest among those with the condition, and management seems to be eyeing FDA approval within 2023. Its financing remains stellar, and all now rests on sound execution. Quoin Pharma Significant […]
Quoin Pharma (QNRX) Aims For Top Spot in Rare Disease Market Read More »
Mobile Global E-Sports Inc. (NASDAQ: MGAM) is an up-and-coming player in the dynamic realm of e-sports and competitive gaming. With a market capitalization below $50 million and exposure limited to the Indian market, MGAM is a small player in a giant space. Market Sees Value for MGAM with New Data Chief Mobile Global E-Sports Inc.
Mobile Global E-Sports (MGAM) Soars With New Hiring Read More »
Electronic Arts Inc. (NASDAQ: EA) is potentially the most prominent name in the gaming industry, with some of the most successful franchises launched into this dynamic market. Its recent third-quarter earnings release points to some near-term pressures, which the management maintains it will overcome. EA Comes in With Mixed Q3 Results Yesterday, Electronic Arts Inc.
Electronic Arts (EA) Remains Confident On Its Market Domination Read More »
Snap Inc. (NASDAQ: SNAP) runs the popular Snapchat platform, which was a tech pioneer in its short video format social site. Its poor results in Q4 point to a worsening climate for social media companies driven by wider macro pressures. Snapchat Reports Slow Q4 Yesterday, Snap Inc. (SNAP) came out with its fourth-quarter results, which
Snap Inc. Continues to Face the Pressure Read More »
The Metals Company Inc. (NASDAQ: TMC) is a deep-sea miner that has been playing all its cards right. 2022 proved to be a stellar year for the company, and the market appears fully confident that this momentum will be pushed on through the upcoming years, despite macroeconomic concerns. The Metals Company Makes Breakthrough in Hidden
The Metals Company (TMC) Pushes On Winning Momentum Read More »
TransCode Therapeutics Inc. (NASDAQ: RNAZ) is a promising biotech company that has been in and out of the market spotlight in recent weeks and months. Its specific area of focus is a specialization on metastatic disease, putting it at the forefront of cancer research. It boasts some key treatment candidates that show significant promise. Positive
TransCode Therapeutics (RNAZ): A Promising Cancer Play Read More »
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.